Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Common Equity (2021 - 2025)

PAVmed (PAVM) has 5 years of Common Equity data on record, last reported at $22.5 million in Q3 2025.

  • For Q3 2025, Common Equity changed N/A year-over-year to $22.5 million; the TTM value through Sep 2025 reached $22.5 million, changed N/A, while the annual FY2024 figure was -$7.0 million, 70.72% up from the prior year.
  • Common Equity reached $22.5 million in Q3 2025 per PAVM's latest filing, down from $28.2 million in the prior quarter.
  • Across five years, Common Equity topped out at $79.4 million in Q4 2021 and bottomed at -$24.0 million in Q4 2023.
  • Average Common Equity over 5 years is $19.6 million, with a median of $22.5 million recorded in 2025.
  • Peak YoY movement for Common Equity: plummeted 2146.02% in 2024, then soared 289.22% in 2025.
  • A 5-year view of Common Equity shows it stood at $79.4 million in 2021, then tumbled by 86.23% to $10.9 million in 2022, then crashed by 319.66% to -$24.0 million in 2023, then surged by 70.72% to -$7.0 million in 2024, then skyrocketed by 420.3% to $22.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $22.5 million in Q3 2025, $28.2 million in Q2 2025, and $38.9 million in Q1 2025.